NextGen Transformative Immunologic Therapies for Human Disease

 Sunday, May 8, 2022     8:00 AM – 10:00 AM ET     Room A107–109

NextGen Transformative Immunologic Therapies for Human Disease

Sponsored by the AAI Clinical Immunology Committee

Chairs

• Jennifer H. Anolik, Univ. of Rochester Med. Ctr., AAI Clinical Immunology Committee Chair
• Erica L. Stone, GigaGen

Speakers

• Jeffrey S. Miller, Univ. of Minnesota, Twin Cities, The next generation of NK cell therapeutics to treat cancer
• Stephanie K. Dougan, Dana-Farber Cancer Inst., Inducing and sustaining tumor-specific memory CD8⁺ T cells
• Samik Basu, Cabaletta Bio, Adoptive immunotherapy for MuSK subtype myasthenia gravis
• S. Alice Long, Benaroya Res. Inst., Treg modulation by IL-2 mutein therapy

Understanding the underlying mechanisms of pathology for disease states has allowed for both the manipulation and targeting of specific aspects of the immune response to alleviate, or in some instances cure, immune and non-immune mediated diseases. But how does basic immunology research evolve into potential therapies, and how do those therapies get developed? And what are the new, up-and-coming therapies currently in development? In this session, four speakers will highlight therapies that are in the pipeline for clinical use and tell their stories, from target identification to their use in clinical trials.